- Home
- FMFC vs CHRS Comparison
FMFC vs CHRS Comparison
Compare FMFC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMFC
- CHRS
- Stock Information
- Founded
- FMFC 2016
- CHRS 2010
- Country
- FMFC Cambodia
- CHRS United States
- Employees
- FMFC N/A
- CHRS N/A
- Industry
- FMFC
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMFC
- CHRS Health Care
- Exchange
- FMFC NYSE
- CHRS Nasdaq
- Market Cap
- FMFC 116.5M
- CHRS 102.0M
- IPO Year
- FMFC 2025
- CHRS 2014
- Fundamental
- Price
- FMFC $7.22
- CHRS $0.88
- Analyst Decision
- FMFC
- CHRS Buy
- Analyst Count
- FMFC 0
- CHRS 3
- Target Price
- FMFC N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FMFC 580.8K
- CHRS 1.4M
- Earning Date
- FMFC 01-01-0001
- CHRS 08-11-2025
- Dividend Yield
- FMFC N/A
- CHRS N/A
- EPS Growth
- FMFC N/A
- CHRS N/A
- EPS
- FMFC 0.01
- CHRS N/A
- Revenue
- FMFC $17,186,677.00
- CHRS $272,251,000.00
- Revenue This Year
- FMFC N/A
- CHRS N/A
- Revenue Next Year
- FMFC N/A
- CHRS $142.61
- P/E Ratio
- FMFC $627.55
- CHRS N/A
- Revenue Growth
- FMFC 3.71
- CHRS 19.87
- 52 Week Low
- FMFC $4.20
- CHRS $0.66
- 52 Week High
- FMFC $7.59
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FMFC N/A
- CHRS 47.28
- Support Level
- FMFC N/A
- CHRS $0.88
- Resistance Level
- FMFC N/A
- CHRS $1.15
- Average True Range (ATR)
- FMFC 0.00
- CHRS 0.08
- MACD
- FMFC 0.00
- CHRS -0.00
- Stochastic Oscillator
- FMFC 0.00
- CHRS 18.26
About FMFC KANDAL M VENTURE LIMITED
Kandal M Venture Ltd is engaged in manufacturing affordable luxury leather goods. The company manufactures handbags, such as shoulder bags, crossbody bags, tote bags, backpacks, top-handle handbags, satchels, and other smaller leather goods, such as wallets. Geographically, the company derives maximum revenue from the United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.